Stock Price Quote

PHARMACIA HEALTHCARE LTD. (MERGED)

NSE : NABSE : 506817ISIN CODE : Industry : Pharmaceuticals & DrugsHouse : MNC
BSE132.850 (0 %)
PREV CLOSE ( ) 132.85
OPEN PRICE ( ) 128.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )128.50 134.80
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year :
Management Info
R A Shah - Chairman Hocine Sidi Said - Managing Director
Registered Office

Address Not Available

Phone Not Available

Email Not Available

Website Not Available

Registrars Details
Not Available
Listing :

NEWS

21Feb Abbott, Ranbaxy Settle Patent Suit
Abbott Laboratories has settled a patent litigation case against Ranbaxy..

Financials

in Millions
QTR Aug 04 ANNUAL 03
Net Profit-25.12
Gross Profit -16.87
Operating Profit -7.97
Net Sales 422.88

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Hester Biosciences (BSE)
peergroup  2498.60 (20.00%)
M.Cap ( in Cr)2125.53
Procter&Gamble Healt (BSE)
peergroup  5061.65 (1.33%)
M.Cap ( in Cr)8402.03
Dr. Reddy's Lab (BSE)
peergroup  6008.70 (0.76%)
M.Cap ( in Cr)100242.96
Natco Pharma (BSE)
peergroup  1201.10 (2.30%)
M.Cap ( in Cr)21512.89
Alembic Pharma (BSE)
peergroup  868.60 (2.77%)
M.Cap ( in Cr)17073.47

Shareholding Pattern

No Data Found

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.